Shire Pharmaceuticals

BMS appoints Judge as senior vice president, human resources

Thursday, February 21, 2013 08:00 AM

Global biopharmaceutical company Bristol-Myers Squibb (BMS) has appointed Ann Powell Judge as senior vice president, Human Resources.

More... »


Ambrx appoints Macartney as CEO

Tuesday, January 8, 2013 08:00 AM

Ambrx, a clinical-stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, has appointed Lawson Macartney, Ph.D., DVM, as president and CEO of the company and a member of the board of directors.

More... »


PharmaNet/i3 names VP and general manager, neuroscience

Monday, July 16, 2012 11:05 AM

PharmaNet/i3, inVentiv Health’s clinical segment, has appointed Robert Lasser, M.D., MBA, vice president and general manager, neuroscience, overseeing the management of all clinical projects handled by PharmaNet/i3’s neuroscience group and the Rater Training Services team. Dr. Lasser will be based in Princeton, N.J.

More... »

Shire acquires Pervasis’ assets

Monday, April 16, 2012 09:47 AM

Shire Pharmaceuticals, a global specialty biopharmaceutical company, will acquire all the assets of Pervasis Therapeutics of Cambridge, Mass.

More... »

Shire to license CNS disorder drug worldwide

Wednesday, March 21, 2012 10:36 AM

Heptares Therapeutics, a U.K.-based drug discovery company, has granted Shire Pharmaceuticals, the global specialty biopharmaceutical company, exclusive worldwide license of novel adenosine A2A antagonist for central nervous system disorders, currently in preclinical development.

More... »

Shire and arGEN-X enter therapeutic antibody alliance

Wednesday, February 29, 2012 04:12 PM

Netherlands-based arGEN-X has entered into an alliance with U.K.-based Shire Pharmaceuticals to create novel therapeutic antibody products against multiple targets submitted by the latter.

More... »

Sangart appoints three to leadership team

Friday, February 17, 2012 12:43 PM

Sangart, a privately held biopharmaceutical company focused on oxygen-therapeutic agents, has appointed three new members to its executive team.

More... »

Vyvanse capsules approved to treat adults with ADHD

Friday, February 10, 2012 12:08 PM

The FDA has approved Vyvanse (lisdexamfetamine dimesylate) capsules as a maintenance treatment for adults with ADHD, according to Shire Pharmaceuticals, a global specialty biopharmaceutical company.

More... »

Shire shows strong profits for Q1

Tuesday, May 3, 2011 01:09 PM

Shire Pharmaceuticals has strong results for the first quarter, with its attention-deficit hyperactivity disorder (ADHD) drugs driving growth, according to Pharma Times.

More... »

Competition aims to recognize, reward skilled U.S. clinical researchers and raise industry profile

Monday, January 24, 2011 12:06 PM

Clinical research associates, study nurses, trial managers and clinical research teams have a chance to win $1,000 prizes in a competition designed to measure their technical and interpersonal skills in a changing global industry and raise the profile of clinical research in the United States.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs